COVID-19 e Doença Cardiovascular: Consequências Diretas e Linhas de Investigação

Autores

DOI:

https://doi.org/10.24950/R/110/20/3/2020

Palavras-chave:

COVID-19, Doenças Cardiovasculares, Infecções por Coronavírus

Resumo

A infeção por SARS-CoV-2 não deixou ninguém incólume ou indiferente. Trouxe implicações profundas na vida diária e na saúde individual, mas também a nível económico e social. A nível da doença cardiovascular, a repercussão da COVID-19 foi enorme. Muito há ainda por saber e a informação é muitas vezes contraditória. Este artigo pretende apontar linhas de investigação que poderão ser úteis para encontrar respostas na relação entre a infeção a SARSCoV- 2 e a doença cardiovascular. Exploramos aquilo que se sabe sobre os efeitos diretos da doença, abordando os mecanismos fisiopatológicos, quer sejam a agressão celular direta, a tempestade inflamatória, a angiopatia trombótica, a hipóxia ou a disfunção de lipoproteínas.

Downloads

Não há dados estatísticos.

Referências

Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol. 2020 (in press). doi:10.1001/jamacardio.2020.0950

Guan WJ, Liang WH, Zhao Y, Liang HR, Chen ZS, for the China Medical Treatment Expert Group for Covid-19. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J. 2020 (in press). doi: 10.1183/13993003.00547-2020

Wang Z, Chen Z, Zhang L, for the China Hypertension Survey Investigators. Status of Hypertension in China: Results From the China Hypertension Survey, 2012-2015. Circulation. 2018;137:2344-56. doi: 10.1161/CIRCULATIONAHA.117.032380.

Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA.

;323:1574-81. doi:10.1001/jama.2020.5394

Barison A, Aimo A, Castiglione V, Arzilli C, Lupón J, Codina P, et al. Cardiovascular disease and COVID-19: les liaisons dangereuses. Eur J Prev Cardiol. 2020 (in press). doi: 10.1177/2047487320924501.

Dixon DL, Van Tassell BW, Vecchié A, Bonaventura A, Talasaz AH, Kakavand H,et al. Cardiovascular Considerations in Treating Patients With Coronavirus Disease 2019 (COVID-19). J Cardiovasc Pharmacol. 2020;75:359-67. doi: 10.1097/FJC.0000000000000836.

Sala S, Peretto G, Gramegna M, Palmisano A, Villatore A, Vignale D, et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur Heart J. 2020 (in press).

doi:10.1093/eurheartj/ehaa286.

Inciardi RM, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D, et al. Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 (in press).doi:10.1001/jamacardio.2020.1096

Boukhris M, Hillani A, Moroni F, Annabi MS, Addad F, Ribeiro MH, et al. Cardiovascular implications of the COVID-19 pandemic: a global perspective. Can J Cardiol. 2020 (in press). doi: 10.1016/j.cjca.2020.05.018

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020;323:1061-9. doi:10.1001/jama.2020.1585

Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J. 2020 (in press). doi: 0.1097/CM9.0000000000000744.

Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 (in press). doi: 10.1001/jamacardio.2020.1017.

Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et al. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. N Engl J Med. 2018;378:345-53. doi: 10.1056/NEJMoa1702090

Stefanini GG, Montorfano M, Trabattoni D, Andreini D, Ferrante G, Ancona M et al. ST-Elevation Myocardial Infarction in Patients with COVID-19: Clinical and Angiographic Outcomes. Circulation. 2020 (in press). doi:10.1161/CIRCULATIONAHA.120.047525

Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options.Cardiovasc Res. 2020 (in press). doi:10.1093/cvr/cvaa106

Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270–3.

Klok FA, Kruip MJ, van der Meer NJ, Arbous MS, Gommers DA, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19.]. Thromb Res. 2020 (in press). doi:10.1016/j.thromres.2020.04.013

Beyrouti R, Adams ME, Benjamin L, Cohen H, Farmer SF, Goh YY, et al. Characteristics of ischaemic stroke associated with COVID-19. J Neurol Neurosurg Psychiatry. 2020 (in press). doi:10.1136/jnnp-2020-323586

Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, et al. Large-Vessel Stroke as a Presenting Feature of Covid-19 in the Young. N Engl J Med. 2020;382:e60. doi:10.1056/NEJMc2009787

Cao W, Li T. COVID-19: towards understanding of pathogenesis. Cell Res. 2020;30:367-369. doi:10.1038/s41422-020-0327-4

Hamming I, Timens W, Bulthuis ML, Lely AT, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. J Pathol. 2004;203:631-7. doi:10.1002/path.1570

Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY,et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int. 2020 (in press). doi:10.1016/j.kint.2020.04.003

Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417-8. doi:10.1016/S0140-6736(20)30937-5

Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020 (in press). doi:10.1056/NEJMoa2015432

Buja LM, Wolf DA, Zhao B, Akkanti B, McDonald M, Lelenwa L, et al. The emerging spectrum of cardiopulmonary pathology of the coronavirus disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of autopsy findings from other United States cities. Cardiovasc Pathol. 2020;48:107233. doi:10.1016/j.carpath.2020.107233

Zhu H, Rhee JW, Cheng P, Waliany S, Chang A, Witteles RM, et al. Cardiovascular Complications in Patients with COVID-19: Consequences of Viral Toxicities and Host Immune Response [published correction appears in Curr Cardiol Rep. 2020;22:36]. Curr Cardiol Rep. 2020;22:32. doi:10.1007/s11886-020-01292-3

Tufan A, Avanoglu Güler A, Matucci-Cerinic M. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk J Med Sci. 2020;50:620-32. doi:10.3906/sag-2004-168

Wang W, He J, Lie p, Huang l, Wu S.. The definition and risks of cytokine release syndrome-like in 11 COVID19-infected pneumonia critically ill patients: disease characteristics and retrospective analysis. Med Rxiv 2020. doi: 10.1101/2020.02.26.20026989

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China [published correction appears in Lancet. 2020]. Lancet. 2020;395:497-506. doi:10.1016/S0140-6736(20)30183-5

Ruan Q, Yang K, Wang W, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China [published correction appears in Intensive Care Med. 2020]. Intensive Care Med. 2020;46:846-8. doi:10.1007/s00134-020-05991-x

Tomasoni D, Italia L, Adamo M, Inciardi RM, Lombardi CM, Solomon SD, et al. COVID 19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease [published online ahead of print, 2020]. Eur J Heart Fail. 2020 (in press). doi:10.1002/ejhf.1871

Rello J, Storti E, Belliato M, Serrano R. Clinical phenotypes of SARS-CoV-2: implications for clinicians and researchers. Eur Respir J. 2020;55:2001028. doi:10.1183/13993003.01028-2020

Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382:1708-20. doi:10.1056/NEJMoa2002032

Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020;17:259-60. doi:10.1038/s41569-020-0360-5

Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth Universal Definition of Myocardial Infarction (2018). J Am Coll Cardiol. 2018;72:2231-64. doi:10.1016/j.jacc.2018.08.1038

Gattinoni L, Coppola S, Cressoni M. COVID-19 does not lead to a “typical” acute respiratory distress syndrome. Am J Respir Crit Care Med. 2020 (in press).

Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A, et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19.]. Ann Intern Med. 2020 (in press). doi:10.7326/M20-2003

Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18:1094-99. doi:10.1111/jth.14817

Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844-7. doi:10.1111/jth.14768

Xie Y, Wang X, Yang P, Zhang S. COVID-19 complicated by acute pulmonary embolism. Radiol Cardiothorac Imaging 2020;2:e200067-e200067

Kreuziger L, Lee A, Garcia D, Cuker A, Cushman M, Connors J. COVID-19 and VTE-anticoagulation. American Society of Hematology - resource for COVID-19 and coagulopathy 2020. Chicago: ASH; 2020.

Barnes GD, Burnett A, Allen A, Blumenstein M, Clark NP, Cuker A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation. J Thromb Thrombolysis. 2020 (in press). doi:10.1007/s11239-020-02138-z

Atallah B, Mallah SI, AlMahmeed W. Anticoagulation in COVID-19.Eur Heart J Cardiovasc Pharmacother. 2020 (in press). doi:10.1093/ehjcvp/pvaa036

Gordon EM, Figueroa DM, Barochia AV, Yao X, Levine SJ. High-density Lipoproteins and Apolipoprotein A-I: Potential New Players in the Prevention and Treatment of Lung Disease. Front Pharmacol. 2016;7:323.

Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM. High-density lipoprotein loses its anti-inflammatory properties during acute influenza A infection. Circulation. 2001;103:2283-88. doi:10.1161/01.

cir.103.18.2283

Downloads

Publicado

30-09-2021

Como Citar

1.
Mamade Y, Mendes I, Balhana S, Pereira CS, Vasoncelos M, Moreira AP, Araújo F. COVID-19 e Doença Cardiovascular: Consequências Diretas e Linhas de Investigação. RPMI [Internet]. 30 de Setembro de 2021 [citado 29 de Março de 2024];27(3):257-63. Disponível em: https://revista.spmi.pt/index.php/rpmi/article/view/127

Edição

Secção

Artigos de Revisão

Artigos mais lidos do(s) mesmo(s) autor(es)